Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera ...

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

Protagonist Therapeutics, Inc.’s PTGX share price has surged by 6.71%, which has investors questioning if this is right time to sell.

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.

It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of ...

In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at ...

Disc Medicine's strong financial position ensures funding through 2028, reducing near-term financing risks. Read why I'm ...

Global Myeloproliferative Disorders Drugs Market is expanding at a significant growth rate due to advancements in targeted therapies, increasing prevalence of myeloproliferative disorders, growing ...

FRIDAY, April 4, 2025 (HealthDay News) -- For patients with myelofibrosis undergoing allogeneic hematopoietic cell ...

Explore why patients with myeloproliferative neoplasmss have unique PCI risks. Learn how to improve post-procedure care.

Discover the connection between blood disorders and cancer development, plus the 5 key signs that require immediate medical ...

As Americans, we can take pride in the fact that we are a nation of givers. And as the economy improves, charitable giving is ...